Amyris (AMRSQ) 10-Q 18 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 10, 2018
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	1,365,916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		50,176,739
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 24,084	$ 57,059
Restricted cash	2,454	2,994
Accounts receivable, net of allowance of $642 as of March 31, 2018 and December 31, 2017	25,730	24,281
Unbilled receivable	9,247	9,340
Inventories	4,998	5,408
Prepaid expenses and other current assets	7,340	5,525
Total current assets	73,853	104,607
Property, plant and equipment, net	12,880	13,892
Unbilled receivable, noncurrent	7,940	7,940
Restricted cash, noncurrent	959	959
Recoverable taxes from Brazilian government entities	1,226	1,445
Other assets	21,302	22,640
Total assets	118,160	151,483
Current liabilities:
Accounts payable	16,054	15,921
Accrued and other current liabilities	26,622	29,402
Deferred revenue	6,466	4,880
Debt, current portion	34,252	36,924
Related party debt, current portion	27,171	20,019
Total current liabilities	110,565	107,146
Long-term debt, net of current portion	62,489	61,893
Related party debt, net of current portion	39,147	46,541
Derivative liabilities	183,189	119,978
Other noncurrent liabilities	8,981	10,632
Total liabilities	404,371	346,190
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized, and 22,171 shares issued and outstanding as of March 31, 2018 and December 31, 2017
Common stock - $0.0001 par value, 250,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 45,850,847 and 45,637,433 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	5	5
Additional paid-in capital - common stock and other	1,050,587	1,048,274
Accumulated other comprehensive loss	(42,293)	(42,156)
Accumulated deficit	(1,300,447)	(1,206,767)
Total Amyris, Inc. stockholders’ deficit	(292,148)	(200,644)
Noncontrolling interest	937	937
Total stockholders' deficit	(291,211)	(199,707)
Total liabilities, mezzanine equity and stockholders' deficit	118,160	151,483
Contingently Redeemable Common Stock [Member]
Current liabilities:
Mezzanine Equity	$ 5,000	$ 5,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance	$ 642	$ 642
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	22,171	22,171
Preferred stock, shares outstanding (in shares)	22,171	22,171
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	45,850,847	45,637,433
Common stock, shares outstanding (in shares)	45,850,847	45,637,433

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue
Revenues	$ 22,998	$ 12,980
Cost and operating expenses
Cost of products sold	5,315	12,768
Research and development	18,813	14,778
Sales, general and administrative	18,757	12,778
Total cost and operating expenses	42,885	40,324
Loss from operations	(19,887)	(27,344)
Other income (expense)
Interest expense	(8,205)	(12,184)
Gain (loss) from change in fair value of derivative instruments	(63,913)	2,339
Gain upon extinguishment of debt		96
Other income (expense), net	509	(319)
Total other expense, net	(71,609)	(10,068)
Loss before income taxes	(91,496)	(37,412)
Benefit from income taxes		41
Net loss attributable to Amyris, Inc.	(91,496)	(37,371)
Less cumulative dividends on Series B preferred stock	(395)
Net loss attributable to Amyris, Inc. common stockholders	$ (91,891)	$ (37,371)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.79)	$ (1.93)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	51,200,922	19,335,948
Product [Member]
Revenue
Revenues	$ 5,195	$ 8,037
Licenses and Royalties [Member]
Revenue
Revenues	11,437	255
Grants and Collaborations [Member]
Revenue
Revenues	$ 6,366	$ 4,688

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues, related party	$ 12,941	$ 0
Product [Member]
Revenues, related party	151	0
Licenses and Royalties [Member]
Revenues, related party	11,400	0
Grants and Collaborations [Member]
Revenues, related party	$ 1,390	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Comprehensive loss:
Net loss attributable to Amyris, Inc.	$ (91,496)	$ (37,371)
Foreign currency translation adjustment, net of tax	(137)	323
Total comprehensive loss attributable to Amyris, Inc.	$ (91,633)	$ (37,048)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Mezzanine Equity, Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	22,171,000	45,637,433,000
Balance at Dec. 31, 2017		$ 5	$ 1,048,274	$ (42,156)	$ (1,206,767)	$ 937	$ 5,000	$ (199,707)
Cumulative effect of change in accounting principle (see "Significant Accounting Policies" in Note 1) (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017					(804)			(804)
Cumulative effect of change in accounting principle (see "Significant Accounting Policies" in Note 1) (Accounting Standards Update 2016-01 [Member]) at Dec. 31, 2017					(1,380)			$ (1,380)
Issuance of common stock upon exercise of warrants (in shares)		162,392						162,392
Issuance of common stock upon exercise of warrants			835					$ 835
Issuance of common stock in private placement, net of issuance costs (in shares)		13,529
Issuance of common stock in private placement, net of issuance costs			92					$ 92
Issuance of common stock upon exercise of stock options (in shares)		7,004						7,004
Issuance of common stock upon exercise of stock options			81					$ 81
Issuance of common stock upon restricted stock settlement (in shares)		30,489
Issuance of common stock upon restricted stock settlement			(66)					(66)
Stock-based compensation			1,278					1,278
Other			93					93
Foreign currency translation adjustment				(137)				(137)
Net loss attributable to Amyris, Inc.					(91,496)			(91,496)
Balance (in shares) at Mar. 31, 2018	22,171,000	45,850,847,000
Balance at Mar. 31, 2018		$ 5	$ 1,050,587	$ (42,293)	$ (1,300,447)	$ 937	$ 5,000	$ (291,211)

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net loss	$ (91,496)	$ (37,371)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,561	2,715
Gain on change in fair value of equity investment	(315)
Loss (gain) on disposal of property, plant and equipment	1,035	(55)
Stock-based compensation	1,278	1,646
Amortization of debt discount	3,016	4,473
Gain upon extinguishment of debt		(96)
Loss (gain) from change in fair value and extinguishment of derivative instruments	63,913	(2,339)
Loss (gain) on foreign currency exchange rates	243	(295)
Changes in assets and liabilities:
Accounts receivable	(926)	5,388
Unbilled receivables	93
Inventories	420	(867)
Prepaid expenses and other assets	(2,268)	(713)
Accounts payable	(108)	450
Accrued and other liabilities	(2,779)	3,515
Deferred revenue	782	(1,844)
Net cash used in operating activities	(25,551)	(25,393)
Cash flows from investing activities
Purchases of property, plant and equipment	(1,202)	(457)
Decrease in short-term investments		329
Net cash used in investing activities	(1,202)	(128)
Cash flows from financing activities
Proceeds from issuance of debt		1,500
Repayments of debt	(6,534)	(5,124)
Principal payments on capital leases	(400)	(627)
Proceeds from issuance of common stock upon exercise of warrants	133
Proceeds from issuance of common stock in private placement	92
Proceeds from exercises of common stock options	81
Employer taxes paid upon vesting of restricted stock units	(66)	(22)
Net cash used in financing activities	(6,694)	(4,273)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(68)	(83)
Net decrease in cash, cash equivalents, and restricted cash	(33,515)	(29,877)
Cash, cash equivalents, and restricted cash at beginning of period	61,012	32,433
Cash, cash equivalents, and restricted cash at end of the period	27,497	2,556
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	24,084	1,297
Restricted cash, current	2,454	301
Restricted cash, noncurrent	959	958
Cash, cash equivalents, and restricted cash at end of the period	27,497	2,556
Supplemental disclosures of cash flow information:
Cash paid for interest	1,815	1,863
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable	264	821
Financing of equipment	91	180
Financing of insurance premium under notes payable		146
Issuance of common stock for settlement of debt principal and interest payments		7,681
Accrued interest added to debt principal	$ 1,211	$ 1,115

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably sourced products into the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce five The Company believes that industrial synthetic biology represents a third On December 28, 2017, 1 $33.0 $12.6 $56.9 $5.7 Concurrent with the sale of Amyris Brasil, the Company and DSM entered into a series of commercial agreements including (i) a license agreement to DSM of its farnesene product for DSM to use in the Vitamin E, lubricant, and flavor and fragrance markets; (ii) a value share agreement that DSM will pay the Company specified royalties representing a portion of the profit on the sale of Vitamin E produced from farnesene under the Nenter Supply Agreement assigned to DSM; (iii) a performance agreement for the Company to perform research and development to optimize farnesene for production and sale of farnesene products; and (iv) a transition services agreement for the Company to provide finance, legal, logistics, and human resource services to support the Brotas 1 six six $27.5 $15.0 2018 2019. $17.8 10, 10 December 31, 2017 ( 10 $25.0 4, 10 The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in 10 December 31, 2017 10 10 X. not not Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2018, $60.8 $59.6 December 31, 2017 $1.3 As of March 31, 2018, $27.4 $163.1 $61.4 $22.5 May 31, 2019 $161.7 $11.0 Cash and cash equivalents of $24.1 March 31, 2018, April 12, 2018 ( 14, not one one not 12 12 third 2018, 2 may may not Significant Accounting Policies Note 1, Basis of Presentation and Summary of Significant Accounting Policies 10 606 606” Revenue from Contracts with Customers 2016 01, Financial Instruments-Overall (Subtopic 825 10 no three March 31, 2018. Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not Disaggregation of Revenue Revenue for the three March 31, 2018 2017, 10, The following table presents revenue by major product and service, as well as, by primary geographical market and is based on the location of the customer: Three Months Ended March 31, (In thousands) 2018 2017 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 1,962 $ — $ 1,208 $ 3,170 $ 1,096 $ 10 $ 1,990 $ 3,096 Europe 2,434 11,437 3,500 17,371 2,558 245 2,573 5,376 Asia 678 — 1,000 1,678 4,308 125 4,433 Brazil 5 — 658 663 19 19 Other 116 — — 116 56 56 $ 5,195 $ 11,437 $ 6,366 $ 22,998 $ 8,037 $ 255 $ 4,688 $ 12,980 The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 No 606. Three Months Ended March 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 5,195 $ — $ 5,195 Licenses and royalties 11,437 (11,437 ) — Grants and collaborations 6,366 444 6,810 Total revenue from all customers $ 22,998 $ (10,993 ) $ 12,005 The Company’s accounting policy under the legacy revenue recognition guidance of ASC 605 1, 8 10 Contract Assets, Contract Liabilities, and Accounts Receivable When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract assets are presented as Unbilled receivables on the consolidated balance sheets. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about unbilled receivables, deferred revenue, and accounts receivable from contracts with customers: (In thousands) March 31, 2018 December 31, 2017 Unbilled receivables, current $ 9,247 $ 9,340 Unbilled receivables, noncurrent $ 7,940 $ 7,940 Deferred revenue, current $ 6,466 $ 4,880 Deferred revenue, noncurrent $ — (1) $ — (1) Accounts receivable, net $ 25,730 $ 24,281 ( 1 $0.4 Unbilled receivables, current and noncurrent, relate to the Company’s right to consideration from DSM for minimum future royalties. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2018 December 31, 2019, Deferred revenue, current increased by $1.6 March 31, 2018 $0.8 606 January 1, 2018 three March 31, 2018. $1.7 three March 31, 2018 Costs to Obtain and Fulfill a Contract We generally do not Remaining Performance Obligations The following table provides information of the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2018. (In thousands) March 31, 2018 Remaining 2018 $ 7,197 2019 8,865 2020 7,656 2021 and thereafter 828 $ 24,546 In accordance with the disclosure provisions of ASC 606, one For descriptions of the Company's other significant accounting policies, see the Company's Annual Report on Form 10 December 31, 2017. Recent Accounting Pronouncements (a) Recent Accounting Standards Pronouncements or Updates Recently Adopted In the three March 31, 2018, Revenue Recognition 606 January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 $0.8 606 605. not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018 $1.4 January 1, 2018 January 1, 2018 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15, 2016 15 January 1, 2018 2016 15, Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not (b) Recent Accounting Standards Pronouncements or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 may Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates, and such differences may Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s condensed consolidated financial statements and the accompanying notes to the condensed consolidated financial statements. The condensed consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the condensed consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model of licensing its technology and earning royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	2. Accounts Receivable, Net Accounts receivable, net is comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Accounts receivable $ 7,035 $ 18,953 Related party accounts receivable 18,695 5,328 $ 25,730 $ 24,281 Inventories Inventories are stated at the lower of cost or net realizable value and are comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Raw materials $ 871 $ 819 Work-in-process 173 364 Finished goods 3,954 4,225 Inventories $ 4,998 $ 5,408 Property, Plant and Equipment, Net Property, plant and equipment, net is comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Machinery and equipment $ 48,911 $ 49,277 Leasehold improvements 40,196 40,036 Computers and software 10,415 9,555 Furniture and office equipment, vehicles and land 3,518 3,415 Construction in progress 17,145 17,438 120,185 119,721 Less: accumulated depreciation and amortization (107,305 ) (105,829 ) Property, plant and equipment, net $ 12,880 $ 13,892 Property, plant and equipment, net includes $3.4 $4.2 March 31, 2018 December 31, 2017, $1.7 $1.6 March 31, 2018 December 31, 2017, Depreciation and amortization expense, including amortization of assets under capital leases was $1.6 $2.7 three March 31, 2018 2017, Other Assets Other assets are comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Contingent consideration $ 8,151 $ 8,151 Prepaid royalty 7,384 7,409 Equity investment in SweeGen 2,168 3,233 Deposits 2,760 2,462 Goodwill 560 560 Other 279 825 Other assets $ 21,302 $ 22,640 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Accrued interest $ 8,011 $ 8,213 Payroll and related expenses 6,797 7,238 SMA relocation accrual 3,571 3,587 Tax-related liabilities 2,524 5,837 Professional services 1,756 1,894 Other 3,963 2,633 Total accrued and other current liabilities $ 26,622 $ 29,402 Other Noncurrent Liabilities Other noncurrent liabilities are comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Deferred rent, net of current portion $ 7,821 $ 7,818 Deferred revenue, net of current portion 383 383 Capital lease obligation, net of current portion 225 217 Other liabilities 552 2,214 Total other noncurrent liabilities $ 8,981 $ 10,632

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	3. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize, for assets or liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: (In thousands) March 31, 2018 December 31, 2017 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit 1,159 — — 1,159 7,813 — — 7,813 Equity investment in SweeGen — 2,168 — 2,168 — — — — Total assets measured and recorded at fair value $ 1,159 $ 2,168 $ — $ 3,327 $ 61,012 $ — $ — $ 61,012 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 15,305 $ 15,305 $ — $ — $ 4,203 $ 4,203 Freestanding derivative instruments in connection with the issuance of equity instruments — — 167,884 167,884 — — 115,775 115,775 Total liabilities measured and recorded at fair value $ — $ — $ 183,189 $ 183,189 $ — $ — $ 119,978 $ 119,978 There were no Equity Investment in SweeGen The Company holds 850,115 December 2016 March 31, 2018, $2.2 2 three March 31, 2018, $0.3 2016 01 January 1, 2018 1. Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 (In thousands) 2018 2017 Balance at January 1 $ 119,978 $ 4,135 (Gain) loss from change in fair value of derivative liabilities 63,913 (1,984 ) Additions — 577 Derecognition upon conversion or extinguishment (702 ) — Balance at March 31 $ 183,189 $ 2,728 The derivative liabilities recognized in connection with the issuance of debt and equity instruments represent the fair value of the make-whole provisions of the Series A and B Preferred Stock as well as the cash and anti-dilution warrants issued concurrently with the Series A, B and D Preferred Stock (see Note 6, 8 10 2014 144A 2015 144A 4, 6, 8 10 The market-based assumptions and estimates used in applying a Monte Carlo simulation approach and Black-Scholes-Merton option value approach for valuing the derivative liabilities in connection with debt and equity instruments include amounts in the following ranges and amounts: March 31, 2018 March 31, 2017 Risk-free interest rate 1.96% - 2.74% 0.74% - 1.30% Risk-adjusted yields 16.30% - 26.43% 12.50% - 22.63% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $6.69 $7.95 Credit spread 14.26% - 24.33% 11.28% - 21.35% Estimated conversion dates 2018 - 2025 2017 - 2019 The valuation of the embedded derivatives in connection with the issuance of debt and equity instruments and freestanding derivative instruments in connection with the issuance of equity instruments can be significantly affected by changes in valuation assumptions. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. A third Changes in Fair Value Changes in the fair value of assets or liabilities measured at fair value on a recurring basis are recognized in “Gain (loss) from change in fair value of derivative instruments" in the condensed consolidated statements of operations. Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using observable market-based inputs (Level 2 3 (In thousands) March 31, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Total debt $ 159,027 $ 163,059 $ 156,900 $ 165,377

Note 4 - Debt

Note 4 - Debt	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Net carrying amounts of debt are as follows: March 31, 2018 December 31, 2017 (In thousands) Principal Unamortized Debt Discount Net Balance Principal Unamortized Debt Discount Net Balance Nonrelated Party Convertible notes 2015 Rule 144A convertible notes $ 37,887 $ (5,866 ) $ 32,021 $ 37,887 $ (6,872 ) $ 31,015 2014 Rule 144A convertible notes 24,004 (2,600 ) 21,404 24,004 (3,170 ) 20,834 December 2017 convertible note 2,500 (10 ) 2,490 5,000 (25 ) 4,975 August 2013 financing convertible notes 4,416 (2,806 ) 1,610 4,009 (2,918 ) 1,091 68,807 (11,282 ) 57,525 70,900 (12,985 ) 57,915 Loans payable and credit facilities Senior secured loan facility 27,316 (136 ) 27,180 28,566 (253 ) 28,313 Ginkgo notes 12,000 (4,803 ) 7,197 12,000 (4,983 ) 7,017 Other loans payable 5,796 (1,256 ) 4,540 6,463 (1,277 ) 5,186 Other credit facilities 305 — 305 381 — 381 45,417 (6,195 ) 39,222 47,410 (6,513 ) 40,897 Subtotal nonrelated party 114,224 (17,477 ) 96,747 118,310 (19,498 ) 98,812 Related Party Related party convertible notes August 2013 financing convertible notes 22,516 665 23,181 21,711 897 22,608 2014 Rule 144A convertible notes 24,705 (3,107 ) 21,598 24,705 (3,784 ) 20,921 R&D note 3,700 — 3,700 3,700 (18 ) 3,682 50,921 (2,442 ) 48,479 50,116 (2,905 ) 47,211 Related party loans payable DSM note 25,000 (7,634 ) 17,366 25,000 (8,039 ) 16,961 Other DSM loan 467 — 467 393 — 393 February 2016 private placement — — — 2,000 — 2,000 25,467 (7,634 ) 17,833 27,393 (8,039 ) 19,354 Subtotal related party 76,388 (10,076 ) 66,312 77,509 (10,944 ) 66,565 Total debt 190,612 (27,553 ) 163,059 195,819 (30,442 ) 165,377 Less: current portion (61,423 ) (56,943 ) Long-term debt, net of current portion $ 101,636 $ 108,434 During the three March 31, 2018, • R&D Note Extension: March 30, 2018, 4, 18, 8 10 March 31, 2018 May 31, 2018, March 31, 2018 May 31, 2018. • Senior Secured Loan Facility Extension: March 30, 2018, 4, 18, 8 10 $5.5 March 31, 2018 May 31, 2018. April 1, 2018 $5.5 5.0%. No three March 31, 2018. Future Minimum Payments Future minimum payments under the Company's debt agreements as of March 31, 2018 not 4, 8 10

Note 5 - Mezzanine Equity

Note 5 - Mezzanine Equity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Mezzanine Equity Disclosure [Text Block]	5. Mezzanine equity is comprised of the following: (In thousands) March 31, 2018 December 31, 2017 Contingently redeemable common stock $ 5,000 $ 5,000 Mezzanine equity at March 31, 2018 December 31, 2017 May 10, 2016 not third $17.10 10%.

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Warrants In connection with various debt and equity transactions (see Note 4, 6, 8 10 three March 31, 2018: Transaction Transaction Type Number Outstanding as of December 31, 2017 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2018 July 2015 private placement Equity 81,197 — — 81,197 July 2015 debt exchange Debt exchange 2,082,010 — — 2,082,010 February 2016 related party private placement Debt 171,429 — — 171,429 May 2017 offerings (Series A and B preferred stock) Equity / debt conversion 18,042,568 — (162,392 ) 17,880,176 August 2017 DSM offering (Series B preferred stock) Equity 3,968,116 — — 3,968,116 August 2017 Vivo offering (Series D preferred stock) Equity 5,575,118 — — 5,575,118 Other — 1,406 — — 1,406 29,921,844 — (162,392 ) 29,759,452 For the three March 31, 2018, $0.1 162,392 At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. may 415 1933, 3.0% no During the three March 31, 2018, 13,529 $7.01 March 31, 2018, $49.9 April 15, 2018,

Note 7 - Variable-interest Enti

Note 7 - Variable-interest Entities and Unconsolidated Investments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	7. Consolidated Variable-interest Entity The table below reflects the carrying value of the Aprinnova JV's assets and liabilities, for which the Company is the primary beneficiary at March 31, 2018: (In thousands) March 31, 2018 December 31, 2017 Assets 36,747 36,781 Liabilities 2,535 3,187 The Aprinnova JV's creditors have recourse only to the assets of the Aprinnova JV. During the three March 31, 2018 2017, no Unconsolidated Investments The Company's unconsolidated investments are summarized as follows: Carrying Value of Investment on Condensed Consolidated Balance Sheets (Amounts in thousands) Amyris Equity Ownership % March 31, 2018 December 31, 2017 Equity-method investments: Novvi LLC 20% $ — $ — Total Amyris BioSolutions B.V. 25% $ — $ — Other unconsolidated equity investment: SweeGeen, Inc. 3% $ 2,168 $ 3,233

Note 8 - Net Loss Per Share Att

Note 8 - Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	8. For the three March 31, 2018 March 31, 2017, The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders: Three Months Ended March 31, 2018 2017 Numerator: Net loss attributable to Amyris, Inc. $ (91,496 ) $ (37,371 ) Less cumulative dividends on Series A and Series B preferred stock (395 ) — Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (91,891 ) $ (37,371 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 51,200,922 19,335,948 Net loss per share, basic and diluted $ (1.79 ) $ (1.93 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock because including them would have been antidilutive: As of March 31, 2018 2017 Stock options to purchase common stock 1,365,447 901,152 Convertible promissory notes (1) 8,347,364 4,855,074 Period-end common stock warrants 29,759,452 334,740 Period-end restricted stock units 706,697 481,603 Period-end preferred stock 4,504,212 — Total potentially dilutive securities excluded from computation of diluted net loss per share 44,683,172 6,572,569 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Contingencies Disclosure [Text Block]	9. Commitments Future minimum payments under the Company's lease obligations as of March 31, 2018 Years ending December 31: (In thousands) Capital Operating Total Lease Obligations 2018 (remaining nine months) $ 475 $ 7,414 $ 7,889 2019 229 8,774 9,003 2020 67 7,035 7,102 2021 — 7,259 7,259 2022 — 7,432 7,432 Thereafter — 3,322 3,322 Total future minimum payments $ 771 $ 41,236 $ 42,007 Less: amount representing interest (34 ) Present value of minimum lease payments 737 Less: current portion (512 ) Long-term portion $ 225 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no March 31, 2018 December 31, 2017 . The Company entered into the FINEP Credit Facility to finance a research and development project on sugarcane-based biodiesel; see Note 4, 8 10 March 31, 2018 December 31, 2017 was R$6.0 $1.8 The Senior Secured Loan Facility (see Note 4, 8 10 first 4, 8 10 first 10% Contingencies The Company has levied indirect taxes on sugarcane-based biodiesel sales that took place several years ago by Amyris Brasil Ltda. (see Note 13, 8 10 The Company and a number of the Company’s current officers and directors are parties to four December 21, 2017, March 9, 2018. March 29, 2018, May 4, 2018 two not 1, 10 The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one

Note 10 - Significant Revenue A

Note 10 - Significant Revenue Agreements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	10. In connection with significant revenue agreements (see below and Note 10, 8 10 and from all other customers, the Company recognized the following revenues for the three March 31, 2018 2017 : Three Months Ended March 31, (In thousands) 2018 2017 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total DSM $ — $ 11,400 $ 1,390 $ 12,790 $ — $ — $ — $ — Givaudan 1,076 — 1,500 2,576 619 — 1,500 2,119 Firmenich 207 37 1,267 1,511 997 245 1,074 2,316 Nenter — — 1,000 1,000 2,309 — — 2,309 DARPA — — 846 846 — — 972 972 Subtotal revenue from significant revenue agreements 1,283 11,437 6,003 18,723 3,925 245 3,546 7,716 Revenue from all other customers 3,912 — 363 4,275 4,112 10 1,142 5,264 Total revenue from all customers $ 5,195 $ 11,437 $ 6,366 $ 22,998 $ 8,037 $ 255 $ 4,688 $ 12,980 Givaudan Agreements In 2015, 2011. 5 2 three 2016, 2 $12.0 $3.0 June 30, 2016; March 31, 2018, $12.0 During the three March 31, 2018, no material changes to significant revenue agreements.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Debt Related party debt March 31, 2018 December 31, 2017 was as follows: March 31, 2018 December 31, 2017 (in thousands) Principal Unamortized Debt Discount Net Balance Principal Unamortized Debt Discount Net Balance Total R&D note $ 3,700 $ — $ 3,700 $ 3,700 $ (18 ) $ 3,682 August 2013 financing convertible notes 22,516 665 23,181 21,711 897 22,608 2014 Rule 144A convertible notes 9,705 (1,263 ) 8,442 9,705 (1,538 ) 8,167 35,921 (598 ) 35,323 35,116 (659 ) 34,457 DSM DSM note 25,000 (7,635 ) 17,365 25,000 (8,039 ) 16,961 Other DSM loan 467 — 467 393 — 393 25,467 (7,635 ) 17,832 25,393 (8,039 ) 17,354 Biolding February 2016 private placement — — — 2,000 — 2,000 Foris 2014 Rule 144A convertible notes 5,000 (541 ) 4,459 5,000 (660 ) 4,340 Temasek 2014 Rule 144A convertible notes 10,000 (1,302 ) 8,698 10,000 (1,586 ) 8,414 $ 76,388 $ (10,076 ) $ 66,312 $ 77,509 $ (10,944 ) $ 66,565 Related Party Accounts Receivable and Unbilled Receivable Related party accounts receivable and unbilled receivable as of March 31, 2018 December 31, 2017 (In thousands) March 31, 2018 December 31, 2017 Accounts receivable, net: DSM $ 18,139 $ 3,483 Novvi 294 1,607 Total 262 238 $ 18,695 $ 5,328 Unbilled receivable, current: DSM $ 9,210 $ 9,340 Unbilled receivable, noncurrent: DSM $ 7,940 $ 7,940 Related Party Joint Ventures See Note 7, 8 10 • Aprinnova joint venture with Nikko • TAB joint venture with Total

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12. The Company’s stock option activity and related information for the three March 31, 2018 Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Granted 54,600 $ 4.95 Exercised (7,004 ) $ 3.68 Forfeited or expired (20,516 ) $ 57.86 Outstanding - March 31, 2018 1,365,447 $ 32.04 7.6 $ 1,632 Vested or expected to vest after March 31, 2018 1,282,903 $ 33.60 7.5 $ 1,525 Exercisable at March 31, 2018 936,291 $ 42.53 7.0 $ 1,114 The Company’s restricted stock units (RSUs) activity and related information for the three March 31, 2018 Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2017 683,554 $ 8.66 1.40 Awarded 60,519 $ 5.01 RSUs released (32,675 ) $ 12.37 RSUs forfeited (4,701 ) $ 8.88 Outstanding - March 31, 2018 706,697 $ 8.16 1.29 Vested or expected to vest after March 31, 2018 563,906 $ 8.42 1.14 Stock-based compensation expense related to options and RSUs granted to employees and non-employees during the three March 31, 2018 2017 Three Months Ended March 31, (In thousands) 2018 2017 Research and development $ 363 $ 484 Sales, general and administrative 915 1,162 Total stock-based compensation expense $ 1,278 $ 1,646 As of March 31, 2018, $5.8 2.4 The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended March 31, 2018 2017 Expected dividend yield — % — % Risk-free interest rate 2.6 % 2.1 % Expected term (in years) 6.13 6.15 Expected volatility 80.5 % 80.0 %

Note 13 - Income Taxes

Note 13 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. The Company recorded income tax provisions for the three March 31, 2018 2017 Three Months Ended March 31, (In thousands) 2018 2017 Benefit from income taxes $ — $ 41 The benefit for income taxes for the three March 31, 2017 no In connection with our adoption of ASC 606 January 1, 2018 No three March 31, 2018, no 606. On December 22, 2017, 2017 not 35% 21%, one December 31, 2017. Based on the Company’s current operations it is anticipated that the only significant current impact of the Act for the Company will be the reduction in the U.S. corporate tax rate. The Act reduces the corporate tax rate to 21 January 1, 2018. December 2017, No. 118 118” not March 31, 2018, not may one 118. March 31, 2018 not

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	14. Warrants Exchange and Exercise On April 12, 2018, 3,616,174 $7.00 fifteen May 2017 6, 8 10 May 2017 3,616,174 $15.9 May 2017 not May 2017 not six no not not 30% thirty

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2018, $60.8 $59.6 December 31, 2017 $1.3 As of March 31, 2018, $27.4 $163.1 $61.4 $22.5 May 31, 2019 $161.7 $11.0 Cash and cash equivalents of $24.1 March 31, 2018, April 12, 2018 ( 14, not one one not 12 12 third 2018, 2 may may not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not Disaggregation of Revenue Revenue for the three March 31, 2018 2017, 10, The following table presents revenue by major product and service, as well as, by primary geographical market and is based on the location of the customer: Three Months Ended March 31, (In thousands) 2018 2017 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 1,962 $ — $ 1,208 $ 3,170 $ 1,096 $ 10 $ 1,990 $ 3,096 Europe 2,434 11,437 3,500 17,371 2,558 245 2,573 5,376 Asia 678 — 1,000 1,678 4,308 125 4,433 Brazil 5 — 658 663 19 19 Other 116 — — 116 56 56 $ 5,195 $ 11,437 $ 6,366 $ 22,998 $ 8,037 $ 255 $ 4,688 $ 12,980 The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 No 606. Three Months Ended March 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 5,195 $ — $ 5,195 Licenses and royalties 11,437 (11,437 ) — Grants and collaborations 6,366 444 6,810 Total revenue from all customers $ 22,998 $ (10,993 ) $ 12,005 The Company’s accounting policy under the legacy revenue recognition guidance of ASC 605 1, 8 10 Contract Assets, Contract Liabilities, and Accounts Receivable When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract assets are presented as Unbilled receivables on the consolidated balance sheets. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about unbilled receivables, deferred revenue, and accounts receivable from contracts with customers: (In thousands) March 31, 2018 December 31, 2017 Unbilled receivables, current $ 9,247 $ 9,340 Unbilled receivables, noncurrent $ 7,940 $ 7,940 Deferred revenue, current $ 6,466 $ 4,880 Deferred revenue, noncurrent $ — (1) $ — (1) Accounts receivable, net $ 25,730 $ 24,281 ( 1 $0.4 Unbilled receivables, current and noncurrent, relate to the Company’s right to consideration from DSM for minimum future royalties. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2018 December 31, 2019, Deferred revenue, current increased by $1.6 March 31, 2018 $0.8 606 January 1, 2018 three March 31, 2018. $1.7 three March 31, 2018 Costs to Obtain and Fulfill a Contract We generally do not Remaining Performance Obligations The following table provides information of the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2018. (In thousands) March 31, 2018 Remaining 2018 $ 7,197 2019 8,865 2020 7,656 2021 and thereafter 828 $ 24,546 In accordance with the disclosure provisions of ASC 606, one For descriptions of the Company's other significant accounting policies, see the Company's Annual Report on Form 10 December 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements (a) Recent Accounting Standards Pronouncements or Updates Recently Adopted In the three March 31, 2018, Revenue Recognition 606 January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 $0.8 606 605. not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018 $1.4 January 1, 2018 January 1, 2018 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15, 2016 15 January 1, 2018 2016 15, Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not (b) Recent Accounting Standards Pronouncements or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 may Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates, and such differences may
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s condensed consolidated financial statements and the accompanying notes to the condensed consolidated financial statements. The condensed consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the condensed consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model of licensing its technology and earning royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no

Note 1 - Basis of Presentatio24

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, (In thousands) 2018 2017 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 1,962 $ — $ 1,208 $ 3,170 $ 1,096 $ 10 $ 1,990 $ 3,096 Europe 2,434 11,437 3,500 17,371 2,558 245 2,573 5,376 Asia 678 — 1,000 1,678 4,308 125 4,433 Brazil 5 — 658 663 19 19 Other 116 — — 116 56 56 $ 5,195 $ 11,437 $ 6,366 $ 22,998 $ 8,037 $ 255 $ 4,688 $ 12,980
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Three Months Ended March 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 5,195 $ — $ 5,195 Licenses and royalties 11,437 (11,437 ) — Grants and collaborations 6,366 444 6,810 Total revenue from all customers $ 22,998 $ (10,993 ) $ 12,005
Contract with Customer, Asset and Liability [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Unbilled receivables, current $ 9,247 $ 9,340 Unbilled receivables, noncurrent $ 7,940 $ 7,940 Deferred revenue, current $ 6,466 $ 4,880 Deferred revenue, noncurrent $ — (1) $ — (1) Accounts receivable, net $ 25,730 $ 24,281
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) March 31, 2018 Remaining 2018 $ 7,197 2019 8,865 2020 7,656 2021 and thereafter 828 $ 24,546

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Accounts receivable $ 7,035 $ 18,953 Related party accounts receivable 18,695 5,328 $ 25,730 $ 24,281
Schedule of Inventory, Current [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Raw materials $ 871 $ 819 Work-in-process 173 364 Finished goods 3,954 4,225 Inventories $ 4,998 $ 5,408
Property, Plant and Equipment [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Machinery and equipment $ 48,911 $ 49,277 Leasehold improvements 40,196 40,036 Computers and software 10,415 9,555 Furniture and office equipment, vehicles and land 3,518 3,415 Construction in progress 17,145 17,438 120,185 119,721 Less: accumulated depreciation and amortization (107,305 ) (105,829 ) Property, plant and equipment, net $ 12,880 $ 13,892
Schedule of Other Assets, Noncurrent [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Contingent consideration $ 8,151 $ 8,151 Prepaid royalty 7,384 7,409 Equity investment in SweeGen 2,168 3,233 Deposits 2,760 2,462 Goodwill 560 560 Other 279 825 Other assets $ 21,302 $ 22,640
Schedule of Accrued and Other Current Liabilities [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Accrued interest $ 8,011 $ 8,213 Payroll and related expenses 6,797 7,238 SMA relocation accrual 3,571 3,587 Tax-related liabilities 2,524 5,837 Professional services 1,756 1,894 Other 3,963 2,633 Total accrued and other current liabilities $ 26,622 $ 29,402
Other Liabilities [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Deferred rent, net of current portion $ 7,821 $ 7,818 Deferred revenue, net of current portion 383 383 Capital lease obligation, net of current portion 225 217 Other liabilities 552 2,214 Total other noncurrent liabilities $ 8,981 $ 10,632

Note 3 - Fair Value Measureme26

Note 3 - Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit 1,159 — — 1,159 7,813 — — 7,813 Equity investment in SweeGen — 2,168 — 2,168 — — — — Total assets measured and recorded at fair value $ 1,159 $ 2,168 $ — $ 3,327 $ 61,012 $ — $ — $ 61,012 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 15,305 $ 15,305 $ — $ — $ 4,203 $ 4,203 Freestanding derivative instruments in connection with the issuance of equity instruments — — 167,884 167,884 — — 115,775 115,775 Total liabilities measured and recorded at fair value $ — $ — $ 183,189 $ 183,189 $ — $ — $ 119,978 $ 119,978
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(In thousands) 2018 2017 Balance at January 1 $ 119,978 $ 4,135 (Gain) loss from change in fair value of derivative liabilities 63,913 (1,984 ) Additions — 577 Derecognition upon conversion or extinguishment (702 ) — Balance at March 31 $ 183,189 $ 2,728
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 31, 2018 March 31, 2017 Risk-free interest rate 1.96% - 2.74% 0.74% - 1.30% Risk-adjusted yields 16.30% - 26.43% 12.50% - 22.63% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $6.69 $7.95 Credit spread 14.26% - 24.33% 11.28% - 21.35% Estimated conversion dates 2018 - 2025 2017 - 2019
Fair Value, by Balance Sheet Grouping [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Total debt $ 159,027 $ 163,059 $ 156,900 $ 165,377

Note 4 - Debt (Tables)

Note 4 - Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2018 December 31, 2017 (In thousands) Principal Unamortized Debt Discount Net Balance Principal Unamortized Debt Discount Net Balance Nonrelated Party Convertible notes 2015 Rule 144A convertible notes $ 37,887 $ (5,866 ) $ 32,021 $ 37,887 $ (6,872 ) $ 31,015 2014 Rule 144A convertible notes 24,004 (2,600 ) 21,404 24,004 (3,170 ) 20,834 December 2017 convertible note 2,500 (10 ) 2,490 5,000 (25 ) 4,975 August 2013 financing convertible notes 4,416 (2,806 ) 1,610 4,009 (2,918 ) 1,091 68,807 (11,282 ) 57,525 70,900 (12,985 ) 57,915 Loans payable and credit facilities Senior secured loan facility 27,316 (136 ) 27,180 28,566 (253 ) 28,313 Ginkgo notes 12,000 (4,803 ) 7,197 12,000 (4,983 ) 7,017 Other loans payable 5,796 (1,256 ) 4,540 6,463 (1,277 ) 5,186 Other credit facilities 305 — 305 381 — 381 45,417 (6,195 ) 39,222 47,410 (6,513 ) 40,897 Subtotal nonrelated party 114,224 (17,477 ) 96,747 118,310 (19,498 ) 98,812 Related Party Related party convertible notes August 2013 financing convertible notes 22,516 665 23,181 21,711 897 22,608 2014 Rule 144A convertible notes 24,705 (3,107 ) 21,598 24,705 (3,784 ) 20,921 R&D note 3,700 — 3,700 3,700 (18 ) 3,682 50,921 (2,442 ) 48,479 50,116 (2,905 ) 47,211 Related party loans payable DSM note 25,000 (7,634 ) 17,366 25,000 (8,039 ) 16,961 Other DSM loan 467 — 467 393 — 393 February 2016 private placement — — — 2,000 — 2,000 25,467 (7,634 ) 17,833 27,393 (8,039 ) 19,354 Subtotal related party 76,388 (10,076 ) 66,312 77,509 (10,944 ) 66,565 Total debt 190,612 (27,553 ) 163,059 195,819 (30,442 ) 165,377 Less: current portion (61,423 ) (56,943 ) Long-term debt, net of current portion $ 101,636 $ 108,434

Note 5 - Mezzanine Equity (Tabl

Note 5 - Mezzanine Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Mezzanine Equity Table [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Contingently redeemable common stock $ 5,000 $ 5,000

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Transaction Transaction Type Number Outstanding as of December 31, 2017 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2018 July 2015 private placement Equity 81,197 — — 81,197 July 2015 debt exchange Debt exchange 2,082,010 — — 2,082,010 February 2016 related party private placement Debt 171,429 — — 171,429 May 2017 offerings (Series A and B preferred stock) Equity / debt conversion 18,042,568 — (162,392 ) 17,880,176 August 2017 DSM offering (Series B preferred stock) Equity 3,968,116 — — 3,968,116 August 2017 Vivo offering (Series D preferred stock) Equity 5,575,118 — — 5,575,118 Other — 1,406 — — 1,406 29,921,844 — (162,392 ) 29,759,452

Note 7 - Variable-interest En30

Note 7 - Variable-interest Entities and Unconsolidated Investments (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Variable Interest Entities [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Assets 36,747 36,781 Liabilities 2,535 3,187
Unconsolidated Investments [Table Text Block]	Carrying Value of Investment on Condensed Consolidated Balance Sheets (Amounts in thousands) Amyris Equity Ownership % March 31, 2018 December 31, 2017 Equity-method investments: Novvi LLC 20% $ — $ — Total Amyris BioSolutions B.V. 25% $ — $ — Other unconsolidated equity investment: SweeGeen, Inc. 3% $ 2,168 $ 3,233

Note 8 - Net Loss Per Share A31

Note 8 - Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2018 2017 Numerator: Net loss attributable to Amyris, Inc. $ (91,496 ) $ (37,371 ) Less cumulative dividends on Series A and Series B preferred stock (395 ) — Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (91,891 ) $ (37,371 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 51,200,922 19,335,948 Net loss per share, basic and diluted $ (1.79 ) $ (1.93 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of March 31, 2018 2017 Stock options to purchase common stock 1,365,447 901,152 Convertible promissory notes (1) 8,347,364 4,855,074 Period-end common stock warrants 29,759,452 334,740 Period-end restricted stock units 706,697 481,603 Period-end preferred stock 4,504,212 — Total potentially dilutive securities excluded from computation of diluted net loss per share 44,683,172 6,572,569

Note 9 - Commitments and Cont32

Note 9 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block]	Years ending December 31: (In thousands) Capital Operating Total Lease Obligations 2018 (remaining nine months) $ 475 $ 7,414 $ 7,889 2019 229 8,774 9,003 2020 67 7,035 7,102 2021 — 7,259 7,259 2022 — 7,432 7,432 Thereafter — 3,322 3,322 Total future minimum payments $ 771 $ 41,236 $ 42,007 Less: amount representing interest (34 ) Present value of minimum lease payments 737 Less: current portion (512 ) Long-term portion $ 225

Note 10 - Significant Revenue33

Note 10 - Significant Revenue Agreements (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Revenue in Connection with Significant Revenue Agreement [Table Text Block]	Three Months Ended March 31, (In thousands) 2018 2017 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total DSM $ — $ 11,400 $ 1,390 $ 12,790 $ — $ — $ — $ — Givaudan 1,076 — 1,500 2,576 619 — 1,500 2,119 Firmenich 207 37 1,267 1,511 997 245 1,074 2,316 Nenter — — 1,000 1,000 2,309 — — 2,309 DARPA — — 846 846 — — 972 972 Subtotal revenue from significant revenue agreements 1,283 11,437 6,003 18,723 3,925 245 3,546 7,716 Revenue from all other customers 3,912 — 363 4,275 4,112 10 1,142 5,264 Total revenue from all customers $ 5,195 $ 11,437 $ 6,366 $ 22,998 $ 8,037 $ 255 $ 4,688 $ 12,980

Note 11 - Related Party Trans34

Note 11 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Related Party Debt [Table Text Block]	March 31, 2018 December 31, 2017 (in thousands) Principal Unamortized Debt Discount Net Balance Principal Unamortized Debt Discount Net Balance Total R&D note $ 3,700 $ — $ 3,700 $ 3,700 $ (18 ) $ 3,682 August 2013 financing convertible notes 22,516 665 23,181 21,711 897 22,608 2014 Rule 144A convertible notes 9,705 (1,263 ) 8,442 9,705 (1,538 ) 8,167 35,921 (598 ) 35,323 35,116 (659 ) 34,457 DSM DSM note 25,000 (7,635 ) 17,365 25,000 (8,039 ) 16,961 Other DSM loan 467 — 467 393 — 393 25,467 (7,635 ) 17,832 25,393 (8,039 ) 17,354 Biolding February 2016 private placement — — — 2,000 — 2,000 Foris 2014 Rule 144A convertible notes 5,000 (541 ) 4,459 5,000 (660 ) 4,340 Temasek 2014 Rule 144A convertible notes 10,000 (1,302 ) 8,698 10,000 (1,586 ) 8,414 $ 76,388 $ (10,076 ) $ 66,312 $ 77,509 $ (10,944 ) $ 66,565
Schedule of Related Party Accounts Receivables [Table Text Block]	(In thousands) March 31, 2018 December 31, 2017 Accounts receivable, net: DSM $ 18,139 $ 3,483 Novvi 294 1,607 Total 262 238 $ 18,695 $ 5,328 Unbilled receivable, current: DSM $ 9,210 $ 9,340 Unbilled receivable, noncurrent: DSM $ 7,940 $ 7,940

Note 12 - Stock-based Compens35

Note 12 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Granted 54,600 $ 4.95 Exercised (7,004 ) $ 3.68 Forfeited or expired (20,516 ) $ 57.86 Outstanding - March 31, 2018 1,365,447 $ 32.04 7.6 $ 1,632 Vested or expected to vest after March 31, 2018 1,282,903 $ 33.60 7.5 $ 1,525 Exercisable at March 31, 2018 936,291 $ 42.53 7.0 $ 1,114
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2017 683,554 $ 8.66 1.40 Awarded 60,519 $ 5.01 RSUs released (32,675 ) $ 12.37 RSUs forfeited (4,701 ) $ 8.88 Outstanding - March 31, 2018 706,697 $ 8.16 1.29 Vested or expected to vest after March 31, 2018 563,906 $ 8.42 1.14
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended March 31, (In thousands) 2018 2017 Research and development $ 363 $ 484 Sales, general and administrative 915 1,162 Total stock-based compensation expense $ 1,278 $ 1,646
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2018 2017 Expected dividend yield — % — % Risk-free interest rate 2.6 % 2.1 % Expected term (in years) 6.13 6.15 Expected volatility 80.5 % 80.0 %

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three Months Ended March 31, (In thousands) 2018 2017 Benefit from income taxes $ — $ 41

Note 1 - Basis of Presentatio37

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Dec. 28, 2017	Mar. 31, 2018	Mar. 31, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax		$ 22,998	$ 12,980
Working Capital		(60,800)			$ (59,600)
Retained Earnings (Accumulated Deficit), Ending Balance		(1,300,447)			(1,206,767)
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total		27,400
Long-term Debt, Total		163,059			165,377
Long-term Debt, Current Maturities, Including Due to Related Parties		61,423			56,943
Convertible Debt, Total		22,500
Long-term Debt, Maturities, Repayments of Principal and Interest in Next 15 Months		161,700
Long-term Debt, Maturities, Repayments of Interest in Next 15 Months		11,000
Cash, Cash Equivalents, and Short-term Investments, Total		24,100
Deferred Revenue, Noncurrent		383			383
Increase (Decrease) in Deferred Revenue		1,600
Contract with Customer, Liability, Current		6,466			4,880
Deferred Revenue, Revenue Recognized		1,700
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance				$ (800)
Contract with Customer, Liability, Current				800
Cumulative Effect of New Accounting Principle in Period of Adoption					(804)
Accounting Standards Update 2016-01 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (1,400)	$ (1,380)
Other Noncurrent Liabilities [Member]
Deferred Revenue, Noncurrent		$ 400
DSM [Member]
Future Minimum Annual Royalty Payments Receivable, Fair Value	$ 17,800
Line of Credit Facility, Maximum Borrowing Capacity	25,000
License [Member] | DSM [Member]
Revenue from Contract with Customer, Including Assessed Tax	27,500
Royalty [Member] | DSM [Member]
Revenue from Contract with Customer, Including Assessed Tax	15,000
Amyris Brasil [Member]
Disposal Group, Including Discontinued Operation, Consideration	56,900
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	5,700
Proceeds from Divestiture of Businesses	33,000
Repayments of Debt	$ 12,600

Note 1 - Basis of Presentatio38

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues	$ 22,998	$ 12,980
Product [Member]
Revenues	5,195	8,037
Licenses and Royalties [Member]
Revenues	11,437	255
Grants and Collaborations [Member]
Revenues	6,366	4,688
UNITED STATES
Revenues	3,170	3,096
UNITED STATES | Product [Member]
Revenues	1,962	1,096
UNITED STATES | Licenses and Royalties [Member]
Revenues		10
UNITED STATES | Grants and Collaborations [Member]
Revenues	1,208	1,990
Europe [Member]
Revenues	17,371	5,376
Europe [Member] | Product [Member]
Revenues	2,434	2,558
Europe [Member] | Licenses and Royalties [Member]
Revenues	11,437	245
Europe [Member] | Grants and Collaborations [Member]
Revenues	3,500	2,573
Asia [Member]
Revenues	1,678	4,433
Asia [Member] | Product [Member]
Revenues	678	4,308
Asia [Member] | Licenses and Royalties [Member]
Revenues
Asia [Member] | Grants and Collaborations [Member]
Revenues	1,000	125
BRAZIL
Revenues	663	19
BRAZIL | Product [Member]
Revenues	5	19
BRAZIL | Licenses and Royalties [Member]
Revenues
BRAZIL | Grants and Collaborations [Member]
Revenues	658
Other Area [Member]
Revenues	116	56
Other Area [Member] | Product [Member]
Revenues	116	56
Other Area [Member] | Licenses and Royalties [Member]
Revenues
Other Area [Member] | Grants and Collaborations [Member]
Revenues

Note 1 - Basis of Presentatio39

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Adoption of ASC 606 (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues	$ 22,998	$ 12,980
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	(10,993)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	12,005
Product [Member]
Revenues	5,195	8,037
Product [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues
Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	5,195
Licenses and Royalties [Member]
Revenues	11,437	255
Licenses and Royalties [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	(11,437)
Licenses and Royalties [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues
Grants and Collaborations [Member]
Revenues	6,366	$ 4,688
Grants and Collaborations [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	444
Grants and Collaborations [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	$ 6,810

Note 1 - Basis of Presentatio40

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Contract Balances (Details) - USD ($) $ in Thousands		Mar. 31, 2018	Dec. 31, 2017
Unbilled receivable		$ 9,247	$ 9,340
Unbilled receivable, noncurrent		7,940	7,940
Deferred revenue, current		6,466	4,880
Deferred revenue, noncurrent	[1]
Accounts receivable, net		$ 25,730	$ 24,281
[1]	Approximately $0.4 million of deferred revenue, noncurrent is presented in Other noncurrent liabilities in the consolidated balance sheets because of its insignificance.

Note 1 - Basis of Presentatio41

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) $ in Thousands	Mar. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01
Remaining performance obligation	$ 7,197
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Remaining performance obligation	8,865
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Remaining performance obligation	7,656
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Remaining performance obligation	828
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Remaining performance obligation	$ 24,546

Note 2 - Balance Sheet Detail42

Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Property, Plant and Equipment, Net, Ending Balance	$ 12,880		$ 13,892
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	107,305		105,829
Depreciation, Depletion and Amortization, Total	1,561	$ 2,715
Property, Plant and Equipment, Including Capital Leases [Member]
Depreciation, Depletion and Amortization, Total	1,600	$ 2,700
Capital Lease Obligations [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	1,700		1,600
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Net, Ending Balance	$ 3,400		$ 4,200

Note 2 - Balance Sheet Detail43

Note 2 - Balance Sheet Details - Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable	$ 7,035	$ 18,953
Related party accounts receivable	18,695	5,328
	$ 25,730	$ 24,281

Note 2 - Balance Sheet Detail44

Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Raw materials	$ 871	$ 819
Work-in-process	173	364
Finished goods	3,954	4,225
Inventories	$ 4,998	$ 5,408

Note 2 - Balance Sheet Detail45

Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, plant and equipment	$ 120,185	$ 119,721
Less: accumulated depreciation and amortization	(107,305)	(105,829)
Property, plant and equipment, net	12,880	13,892
Machinery and Equipment [Member]
Property, plant and equipment	48,911	49,277
Leasehold Improvements [Member]
Property, plant and equipment	40,196	40,036
Computer Equipment and Software [Member]
Property, plant and equipment	10,415	9,555
Furniture and Office Equipment, Vehicles and Land [Member]
Property, plant and equipment	3,518	3,415
Construction in Progress [Member]
Property, plant and equipment	$ 17,145	$ 17,438

Note 2 - Balance Sheet Detail46

Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Contingent consideration	$ 8,151	$ 8,151
Prepaid royalty	7,384	7,409
Equity investment in SweeGen	2,168	3,233
Deposits	2,760	2,462
Goodwill	560	560
Other	279	825
Other assets	$ 21,302	$ 22,640

Note 2 - Balance Sheet Detail47

Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accrued interest	$ 8,011	$ 8,213
Payroll and related expenses	6,797	7,238
SMA relocation accrual	3,571	3,587
Tax-related liabilities	2,524	5,837
Professional services	1,756	1,894
Other	3,963	2,633
Total accrued and other current liabilities	$ 26,622	$ 29,402

Note 2 - Balance Sheet Detail48

Note 2 - Balance Sheet Details - Other Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Deferred rent, net of current portion	$ 7,821	$ 7,818
Deferred revenue, net of current portion	383	383
Capital lease obligation, net of current portion	225	217
Other liabilities	552	2,214
Total other noncurrent liabilities	$ 8,981	$ 10,632

Note 3 - Fair Value Measureme49

Note 3 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Equity Securities, FV-NI	$ 2,168		$ 3,233
Equity Securities, FV-NI, Unrealized Gain	$ 315
SweeGen Common Stock [Member]
Equity Securities, Number of Unregistered Shares Hold	850,115
Equity Securities, FV-NI, Unrealized Gain	$ 300
SweeGen Common Stock [Member] | Other Noncurrent Assets [Member]
Equity Securities, FV-NI	$ 2,200		$ 2,000

Note 3 - Fair Value Measureme50

Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Equity investment in SweeGen	$ 2,168	$ 3,233
Fair Value, Measurements, Recurring [Member]
Money market funds		53,199
Certificates of deposit	1,159	7,813
Equity investment in SweeGen	2,168
Total assets measured and recorded at fair value	3,327	61,012
Embedded derivatives in connection with the issuance of debt and equity instruments	15,305	4,203
Freestanding derivative instruments in connection with the issuance of equity instruments	167,884	115,775
Total liabilities measured and recorded at fair value	183,189	119,978
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds		53,199
Certificates of deposit	1,159	7,813
Equity investment in SweeGen
Total assets measured and recorded at fair value	1,159	61,012
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds
Certificates of deposit
Equity investment in SweeGen	2,168
Total assets measured and recorded at fair value	2,168
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds
Certificates of deposit
Equity investment in SweeGen
Total assets measured and recorded at fair value
Embedded derivatives in connection with the issuance of debt and equity instruments	15,305	4,203
Freestanding derivative instruments in connection with the issuance of equity instruments	167,884	115,775
Total liabilities measured and recorded at fair value	$ 183,189	$ 119,978

Note 3 - Fair Value Measureme51

Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Balance, compound embedded derivative liabilities	$ 119,978	$ 4,135
(Gain) loss from change in fair value of derivative liabilities	63,913	(1,984)
Additions		577
Derecognition upon conversion or extinguishment	(702)
Balance, compound embedded derivative liabilities	$ 183,189	$ 2,728

Note 3 - Fair Value Measureme52

Note 3 - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2018$ / shares	Dec. 31, 2017$ / shares
Share Price	$ 6.69	$ 7.95
Measurement Input, Price Volatility [Member]
Risk-free interest rate		45
Measurement Input, Probability of Change in Control [Member]
Risk-free interest rate	5	5
Minimum [Member]
Estimated conversion dates	2,018	2,017
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate	1.96	0.74
Minimum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Risk-free interest rate	16.3	12.5
Minimum [Member] | Measurement Input, Price Volatility [Member]
Risk-free interest rate	45
Minimum [Member] | Measurement Input, Credit Spread [Member]
Risk-free interest rate	14.26	11.28
Maximum [Member]
Estimated conversion dates	2,025	2,019
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate	2.74	1.3
Maximum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Risk-free interest rate	26.43	22.63
Maximum [Member] | Measurement Input, Price Volatility [Member]
Risk-free interest rate	80
Maximum [Member] | Measurement Input, Credit Spread [Member]
Risk-free interest rate	24.33	21.35

Note 3 - Fair Value Measureme53

Note 3 - Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Total debt	$ 159,027	$ 156,900
Reported Value Measurement [Member]
Total debt	$ 163,059	$ 165,377

Note 4 - Debt (Details Textual)

Note 4 - Debt (Details Textual) - USD ($) $ in Thousands	May 31, 2018	Mar. 31, 2018	May 31, 2018	Mar. 31, 2018
Debt Conversion, Original Debt, Amount				$ 0
Stegodon [Member] | Loan and Security Agreement [Member]
Repayments of Lines of Credit		$ 5,500
Stegodon [Member] | Loan and Security Agreement [Member] | Scenario, Forecast [Member]
Repayments of Lines of Credit	$ 5,500
Debt Instrument, Interest Rate, Increase (Decrease)			5.00%

Note 4 - Debt - Debt Components

Note 4 - Debt - Debt Components (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt, principal	$ 190,612	$ 195,819
Unamortized debt (discount) premium	(27,553)	(30,442)
Debt	163,059	165,377
Debt, current	61,423	56,943
Debt, noncurrent	101,636	108,434
Convertible Debt [Member]
Debt, principal	68,807	70,900
Unamortized debt (discount) premium	(11,282)	(12,985)
Debt	57,525	57,915
Convertible Debt [Member] | The 2015 144A Notes [Member]
Debt, principal	37,887	37,887
Unamortized debt (discount) premium	(5,866)	(6,872)
Debt	32,021	31,015
Convertible Debt [Member] | The 2014 144A Notes [Member]
Debt, principal	24,004	24,004
Unamortized debt (discount) premium	(2,600)	(3,170)
Debt	21,404	20,834
Convertible Debt [Member] | December 2017 Convertible Note [Member]
Debt, principal	2,500	5,000
Unamortized debt (discount) premium	(10)	(25)
Debt	2,490	4,975
Convertible Debt [Member] | August 2013 Convertible Notes [Member]
Debt, principal	4,416	4,009
Unamortized debt (discount) premium	(2,806)	(2,918)
Debt	1,610	1,091
Loans Payable [Member]
Debt, principal	45,417	47,410
Unamortized debt (discount) premium	(6,195)	(6,513)
Debt	39,222	40,897
Loans Payable [Member] | Senior Secured Convertible Note [Member]
Debt, principal	27,316	28,566
Unamortized debt (discount) premium	(136)	(253)
Debt	27,180	28,313
Loans Payable [Member] | Ginkgo Collaboration Note [Member]
Debt, principal	12,000	12,000
Unamortized debt (discount) premium	(4,803)	(4,983)
Debt	7,197	7,017
Loans Payable [Member] | Other Loans Payable [Member]
Debt, principal	5,796	6,463
Unamortized debt (discount) premium	(1,256)	(1,277)
Debt	4,540	5,186
Loans Payable [Member] | Other Credit Facilities [Member]
Debt, principal	305	381
Unamortized debt (discount) premium
Debt	305	381
Nonrelated Party Debt [Member]
Debt, principal	114,224	118,310
Unamortized debt (discount) premium	(17,477)	(19,498)
Debt	96,747	98,812
Related Party Convertible Notes [Member]
Debt, principal	50,921	50,116
Unamortized debt (discount) premium	(2,442)	(2,905)
Debt	48,479	47,211
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member]
Debt, principal	24,705	24,705
Unamortized debt (discount) premium	(3,107)	(3,784)
Debt	21,598	20,921
Related Party Convertible Notes [Member] | August 2013 Convertible Notes [Member]
Debt, principal	22,516	21,711
Unamortized debt (discount) premium	665	897
Debt	23,181	22,608
Related Party Convertible Notes [Member] | Secured R&D Notes [Member]
Debt, principal	3,700	3,700
Unamortized debt (discount) premium		(18)
Debt	3,700	3,682
Related Party Loan Payable [Member]
Debt, principal	25,467	27,393
Unamortized debt (discount) premium	(7,634)	(8,039)
Debt	17,833	19,354
Related Party Loan Payable [Member] | Other Loans Payable [Member]
Debt, principal	467	393
Unamortized debt (discount) premium
Debt	467	393
Related Party Loan Payable [Member] | DSM Note [Member]
Debt, principal	25,000	25,000
Unamortized debt (discount) premium	(7,634)	(8,039)
Debt	17,366	16,961
Related Party Loan Payable [Member] | Private Placement February 2016 [Member]
Debt, principal		2,000
Unamortized debt (discount) premium
Debt		2,000
Related Party Debt [Member]
Debt, principal	76,388	77,509
Unamortized debt (discount) premium	(10,076)	(10,944)
Debt	$ 66,312	66,565
Related Party Debt [Member] | DSM Note [Member]
Debt		$ 16,961

Note 5 - Mezzanine Equity (Deta

Note 5 - Mezzanine Equity (Details Textual) - $ / shares	Apr. 08, 2016	Mar. 31, 2018	Dec. 31, 2017
Share Price		$ 6.69	$ 7.95
Gates Foundation Purchase Agreement [Member]
Share Price	$ 17.10
Compound Annual Return	10.00%

Note 5 - Mezzanine Equity - Mez

Note 5 - Mezzanine Equity - Mezzanine Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Contingently Redeemable Common Stock [Member]
Mezzanine Equity	$ 5,000	$ 5,000

Note 6 - Stockholders' Defici58

Note 6 - Stockholders' Deficit (Details Textual) - USD ($)	Mar. 08, 2016	Mar. 31, 2018	Mar. 31, 2017
Proceeds from Warrant Exercises		$ 133,000
Stock Issued During Period, Shares, Warrants Exercised		162,392
Stock Issued During Period, Value, New Issues		$ 92,000
At the Market Offering [Member]
Common Stock, Value, Subscriptions	$ 50,000,000	49,900,000
Commission Rate	3.00%
Stock Issued During Period, Value, New Issues		$ 13,529
Shares Issued, Price Per Share		$ 7.01

Note 6 - Stockholders' Defici59

Note 6 - Stockholders' Deficit - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2018shares
Number outstanding, beginning balance (in shares)	29,921,844
Additional Warrants Issued (in shares)
Exercises (in shares)	(162,392)
Number outstanding, ending balance (in shares)	29,759,452
Warrant 1 [Member]
Number outstanding, beginning balance (in shares)	81,197
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	81,197
Warrant 2 [Member]
Number outstanding, beginning balance (in shares)	2,082,010
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	2,082,010
Warrant 3 [Member]
Number outstanding, beginning balance (in shares)	171,429
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	171,429
Warrant 4 [Member]
Number outstanding, beginning balance (in shares)	18,042,568
Additional Warrants Issued (in shares)
Exercises (in shares)	(162,392)
Number outstanding, ending balance (in shares)	17,880,176
Warrant 5 [Member]
Number outstanding, beginning balance (in shares)	3,968,116
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	3,968,116
Warrant 6 [Member]
Number outstanding, beginning balance (in shares)	5,575,118
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	5,575,118
Warrant 7 [Member]
Number outstanding, beginning balance (in shares)	1,406
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	1,406

Note 7 - Variable-interest En60

Note 7 - Variable-interest Entities and Unconsolidated Investments - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Assets	$ 36,747	$ 36,781
Liabilities	$ 2,535	$ 3,187

Note 7 - Variable-interest En61

Note 7 - Variable-interest Entities and Unconsolidated Investments - Unconsolidated Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Equity investment in SweeGen	$ 2,168	$ 3,233
Novvi LLC [Member]
Equity-method investment, percentage	20.00%
Equity-method investment
Total Amyris Biosolutions B.V. [Member]
Equity-method investment, percentage	25.00%
Equity-method investment
SweeGen, Inc. [Member]
Equity securities investment	3.00%
Equity investment in SweeGen	$ 2,168	$ 3,233

Note 8 - Net Loss Per Share A62

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net loss attributable to Amyris, Inc.	$ (91,496)	$ (37,371)
Less cumulative dividends on Series A and Series B preferred stock	(395)
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted	$ (91,891)	$ (37,371)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	51,200,922	19,335,948
Net loss per share, basic and diluted (in dollars per share)	$ (1.79)	$ (1.93)

Note 8 - Net Loss Per Share A63

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Antidilutive securities (in shares)		44,683,172	6,572,569
Common Stock Subject to Repurchase [Member]
Antidilutive securities (in shares)		1,365,447	901,152
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	8,347,364	4,855,074
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		29,759,452	334,740
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		706,697	481,603
Period-end Preferred Stock [Member]
Antidilutive securities (in shares)		4,504,212
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Cont64

Note 9 - Commitments and Contingencies (Details Textual) $ in Thousands, R$ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2018USD ($)	Mar. 31, 2018BRL (R$)	Dec. 31, 2017USD ($)	Dec. 31, 2017BRL (R$)
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net, Ending Balance	$ 0		$ 0
Equity Interest of Aprinnova JV Pledge as Collateral [Member]
Collateral, Percentage of Equity Interest in VIE	10.00%	10.00%
FINEP Credit Facility [Member] | Chattel Mortgage [Member]
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired	$ 1,800	R$ 6	$ 1,800	R$ 6

Note 9 - Commitments and Cont65

Note 9 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Capital leases2018 (remaining nine months)	$ 475
Operating leases2018 (remaining nine months)	7,414
Total lease obligations 2018 (remaining nine months)	7,889
Capital leases 2019	229
Operating leases 2019	8,774
Total lease obligations 2019	9,003
Capital leases 2020	67
Operating leases 2020	7,035
Total lease obligations 2020	7,102
Capital leases 2021
Operating leases 2021	7,259
Total lease obligations 2021	7,259
Capital leases 2022
Operating leases 2022	7,432
Total lease obligations 2022	7,432
Capital leases thereafter
Operating leases thereafter	3,322
Total lease obligations thereafter	3,322
Total future minimum capital lease payments	771
Total future minimum operating lease payments	41,236
Total future minimum lease payments	42,007
Less: amount representing interest	(34)
Present value of minimum lease payments	737
Less: current portion	(512)
Capital lease obligation, net of current portion	$ 225	$ 217

Note 10 - Significant Revenue66

Note 10 - Significant Revenue Agreements (Details Textual) - Givaudan International, SA [Member] - Collaborative Arrangement [Member] - USD ($) $ in Millions	1 Months Ended	21 Months Ended
	Jun. 30, 2016	Mar. 31, 2018
Receivable from Collaborators	$ 12
Semi-annual Installments from Collaborators, Amount	$ 3
Proceeds from Collaborators		$ 12

Note 10 - Significant Revenue67

Note 10 - Significant Revenue Agreements - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues	$ 22,998	$ 12,980
Significant Revenue Agreement [Member]
Revenues	18,723	7,716
DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	12,790
Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	2,576	2,119
Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	1,511	2,316
Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues	1,000	2,309
DARPA [Member] | Significant Revenue Agreement [Member]
Revenues	846	972
All Other Customers [Member]
Revenues	4,275	5,264
Renewable Products [Member]
Revenues	5,195	8,037
Renewable Products [Member] | Significant Revenue Agreement [Member]
Revenues	1,283	3,925
Renewable Products [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues
Renewable Products [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	1,076	619
Renewable Products [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	207	997
Renewable Products [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues		2,309
Renewable Products [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues
Renewable Products [Member] | All Other Customers [Member]
Revenues	3,912	4,112
Licenses and Royalties [Member]
Revenues	11,437	255
Licenses and Royalties [Member] | Significant Revenue Agreement [Member]
Revenues	11,437	245
Licenses and Royalties [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	11,400
Licenses and Royalties [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	37	245
Licenses and Royalties [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | All Other Customers [Member]
Revenues		10
Grants and Collaborations [Member]
Revenues	6,366	4,688
Grants and Collaborations [Member] | Significant Revenue Agreement [Member]
Revenues	6,003	3,546
Grants and Collaborations [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	1,390
Grants and Collaborations [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	1,500	1,500
Grants and Collaborations [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	1,267	1,074
Grants and Collaborations [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues	1,000
Grants and Collaborations [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues	846	972
Grants and Collaborations [Member] | All Other Customers [Member]
Revenues	$ 363	$ 1,142

Note 11 - Related Party Trans68

Note 11 - Related Party Transactions - Related Party Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Related party debt, gross	$ 190,612	$ 195,819
Unamortized debt (discount) premium	(27,553)	(30,442)
Due to related parties, net	163,059	165,377
Related Party Debt [Member]
Related party debt, gross	76,388	77,509
Unamortized debt (discount) premium	(10,076)	(10,944)
Due to related parties, net	66,312	66,565
Related Party Debt [Member] | Total [Member]
Related party debt, gross	35,921	35,116
Unamortized debt (discount) premium	(598)	(659)
Due to related parties, net	35,323	34,457
Related Party Debt [Member] | DSM International B.V. [Member]
Related party debt, gross	25,467	25,393
Unamortized debt (discount) premium	(7,635)	(8,039)
Due to related parties, net	17,832	17,354
Related Party Debt [Member] | Foris Ventures, LLC [Member]
Related party debt, gross	76,388	77,509
Unamortized debt (discount) premium	(10,076)	(10,944)
Due to related parties, net	66,312	66,565
Related Party Debt [Member] | R&D Note [Member] | Total [Member]
Related party debt, gross	3,700	3,700
Unamortized debt (discount) premium		(18)
Due to related parties, net	3,700	3,682
Related Party Debt [Member] | August 2013 Convertible Notes [Member] | Total [Member]
Related party debt, gross	22,516	21,711
Unamortized debt (discount) premium	665	897
Due to related parties, net	23,181	22,608
Related Party Debt [Member] | The 2014 144A Notes [Member] | Total [Member]
Related party debt, gross	9,705	9,705
Unamortized debt (discount) premium	(1,263)	(1,538)
Due to related parties, net	8,442	8,167
Related Party Debt [Member] | DSM Note [Member]
Due to related parties, net		16,961
Related Party Debt [Member] | DSM Note [Member] | DSM International B.V. [Member]
Related party debt, gross	25,000	25,000
Unamortized debt (discount) premium	(7,635)	(8,039)
Due to related parties, net	17,365
Related Party Debt [Member] | Other Loans Payable [Member] | DSM International B.V. [Member]
Related party debt, gross	467	393
Unamortized debt (discount) premium
Due to related parties, net	467	393
Related Party Debt [Member] | Private Placement February 2016 [Member] | Biolding Investment SA [Member]
Related party debt, gross		2,000
Unamortized debt (discount) premium
Due to related parties, net		2,000
Related Party Debt [Member] | Related Party 2014 144A Convertible Notes [Member] | Foris Ventures, LLC [Member]
Related party debt, gross	5,000	5,000
Unamortized debt (discount) premium	(541)	(660)
Due to related parties, net	4,459	4,340
Related Party Debt [Member] | Related Party 2014 144A Convertible Notes [Member] | Temasek [Member]
Related party debt, gross	10,000	10,000
Unamortized debt (discount) premium	(1,302)	(1,586)
Due to related parties, net	$ 8,698	$ 8,414

Note 11 - Related Party Trans69

Note 11 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable, net	$ 18,695	$ 5,328
Unbilled receivable, current	9,247	9,340
Unbilled receivable, noncurrent	7,940	7,940
DSM International B.V. [Member]
Accounts receivable, net	18,139	3,483
Unbilled receivable, current	9,210	9,340
Unbilled receivable, noncurrent	7,940	7,940
Novvi LLC [Member]
Accounts receivable, net	294	1,607
Total [Member]
Accounts receivable, net	$ 262	$ 238

Note 12 - Stock-based Compens70

Note 12 - Stock-based Compensation (Details Textual) - Employee Stock Option [Member] $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 5.8
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 146 days

Note 12 - Stock-based Compens71

Note 12 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Outstanding (in shares)	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 33.40
Outstanding, weighted average remaining contractual life (Year)	7 years 219 days	7 years 255 days
Outstanding, aggregate intrinsic value	$ 1,632	$ 97
Granted (in shares)	54,600
Granted, weighted average exercise price (in dollars per share)	$ 4.95
Exercised (in shares)	(7,004)
Exercised, weighted average exercise price (in dollars per share)	$ 3.68
Forfeited or expired (in shares)	(20,516)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 57.86
Outstanding (in shares)	1,365,447	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 32.04	$ 33.40
Vested or expected to vest after March 31, 2018 (in shares)	1,282,903
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share)	$ 33.60
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year)	7 years 182 days
Vested and expected to vest after December 31, 2016, aggregate intrinsic value	$ 1,525
Exercisable at March 31, 2018 (in shares)	936,291
Exercisable at December 31, 2016, weighted average exercise price (in dollars per share)	$ 42.53
Exercisable at December 31, 2016, weighted average remaining contractual life (Year)	7 years
Exercisable at December 31, 2016, aggregate intrinsic value	$ 1,114

Note 12 - Stock-based Compens72

Note 12 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Outstanding, RSUs (in shares)	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 8.66
Outstanding, weighted average remaining contractual life (Year)	1 year 105 days	1 year 146 days
Awarded (in shares)	60,519
Awarded (in dollars per share)	$ 5.01
RSUs released (in shares)	(32,675)
RSUs released (in dollars per share)	$ 12.37
RSUs forfeited (in shares)	(4,701)
RSUs forfeited (in dollars per share)	$ 8.88
Outstanding, RSUs (in shares)	706,697	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 8.16	$ 8.66
Vested or expected to vest after March 31, 2018 (in shares)	563,906
Vested or expected to vest after March 31, 2018 (in dollars per share)	$ 8.42
Vested or expected to vest after March 31, 2018 (Year)	1 year 51 days

Note 12 - Stock-based Compens73

Note 12 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Allocated share-based compensation expense	$ 1,278	$ 1,646
Research and Development Expense [Member]
Allocated share-based compensation expense	363	484
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 915	$ 1,162

Note 12 - Stock-based Compens74

Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Expected dividend yield
Risk-free interest rate	2.60%	2.10%
Expected term (in years) (Year)	6 years 47 days	6 years 54 days
Expected volatility	80.50%	80.00%

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Tax Expense (Benefit), Total		$ (41)
Accounting Standards Update 2014-09 [Member]
Income Tax Expense (Benefit), Total	$ 0

Note 13 - Income Taxes - Schedu

Note 13 - Income Taxes - Schedule of Income Tax Provisions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Benefit from income taxes		$ 41

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Apr. 12, 2018	Mar. 31, 2018	Mar. 31, 2017
Class of Warrants or Right, Issued in Period
Proceeds from Warrant Exercises		$ 133
Subsequent Event [Member] | May 2017 Warrants [Member]
Class of Warrants or Right, Issued in Period	3,616,174
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7
Class of Warrant or Right, Term	1 year 90 days
Proceeds from Warrant Exercises	$ 15,900